ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
August 04 2014 - 1:45PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the following
presentation by Company management at an upcoming investor
conference will be webcast:
- 34th Annual Canaccord
Genuity Growth Conference3:30pm ET, August 13, Boston, MA
The webcast will be accessible live through the “Investor
Information” section of the Company’s website, www.immunogen.com; a
replay will be available at the same location for approximately a
week.
The Company is also participating in the UBS 2014 Biotech Summer
1x1 Conference August 7, 2014 in Boston, MA.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024